Aivita Biomedical announced that the company has signed a deal with custom formulator and beauty product developer Lacore Laboratories.
The deal allows for the use of Aivita's proprietary actives complex in a new line of skincare products to be distributed by Lacore's subsidiary Generation New Online across Asia, including Hong Kong, Taiwan, Singapore, Malaysia and Mainland China.
Aivita's proprietary active technology is a science-based multi-functional ingredient complex and delivery system which captures the natural cell messaging system and ingredients of skin stem cells. The active contains a complete and balanced mix of all the naturally-occurring, revitalizing factors present in a young skin environment.
"Lacore brings unique capabilities to Aivita, including their cultural knowledge of product preferences and their distribution prowess throughout Asia," said Dr. Hans Keirstead, Chairman and CEO of Aivita Biomedical. "We're thrilled to be bringing our revolutionary active technology to consumers throughout the world."
Sales of Aivita's skincare products support the Company's clinical cancer development programs, including an active Phase II clinical trial for women with ovarian cancer.
Aivita Biomedical is a privately held company that aids in the advancement of commercial and clinical-stage programs that use curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth to enable safe, efficient and economical manufacturing systems that support its commercial line of skin care products.